A Phase 3 interventional study of placebo and Varenicline in Smoking Cessation, sponsored by Pfizer. Completed at 39 sites in 15 countries. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-04-05.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.
Among the 110 studies testing varenicline in Smoking Cessation, this one is the 14th largest by enrollment, is one of 2 that started in 2006, is one of 24 in phase 3, and was the 11th registered.
1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.
Browse Smoking Cessation studies →5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 21+
University of Colorado, Denver · Sites in United States, India
Ages 18+
Johns Hopkins University · Sites in South Africa
Ages 18+
University of Maryland, Baltimore · Sites in Botswana
Ages 18+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.
This study: 35 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 25 · Phase 3 30 · Phase 4 47
First in 2000; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 714 is above the median of 164 across 1,424 interventional studies indexed under Smoking Cessation.
Median enrollment 209 across the 110 interventional studies. Of the 97 that completed or were terminated, 61 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 110 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
44 studies in Smoking Cessation by Pfizer: none open now, none under way, none of them phase 3. Of 43 finished, 23 (53%) have results posted.
Among the 44 studies in Smoking Cessation by Pfizer, this one is the 9th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2006, is one of 10 in phase 3, and was the 11th registered.
Pfizer’s Smoking Cessation studies by the year they started, since 2000.
2 of the studies testing varenicline in Smoking Cessation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05413122Phase 3Johns Hopkins UniversityEvaluating Smoking Cessation Interventions for PWH in South Africa | 2027-08-31 |
| NCT05694637University of Maryland, BaltimoreBotswana Smoking and Abstinence Reinforcement Trial | 2027-02-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 110 studies testing varenicline in Smoking Cessation, from their registry updates:
Among Pfizer’s 44 in Smoking Cessation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to determine whether or not varenicline will help people with cardiovascular disease quit smoking and to confirm it is safe in these patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: placebo
Drug: Varenicline
1 mg placebo twice daily by mouth for 12 weeks
1 mg twice daily by mouth for 12 weeks
Also known as: Chantix, Champix
Number of Responders With Carbon Monoxide (CO) Confirmed 4-week Continuous Quit Rate (CQR) for Last 4 Weeks of Treatment (Trtmt)
Participants considered Responders (4-week CQR \<=10 parts per million \<ppm\>) through reports of cigarette or other nicotine use since last study visit, confirmed by measurement of end-expiratory exhaled carbon monoxide (CO). If any CO measurement at a particular timepoint was \>10 ppm, subject was considered to be Non-Responder at that timepoint.
Time frame: weeks 9 through 12
Number of Responders With Continuous Abstinence (CA) Through Week 52
Responders: participants who remained abstinent based on 'since the last contact' question in Nicotine Use Inventory 1) "Has participant smoked any cigarettes (even a puff) since last contact?" = No AND 2) "Has participant used any other tobacco products... since last contact?" = No. Participant a non-responder if expired CO \> 10 ppm.
Time frame: Week 9 through Week 52
Number of Long-Term Quit Responders
Responders: participants were considered Long Term Quit responders if 1) they were responders for the primary endpoint (the 4-week CQR for Weeks 9-12) and 2) had no more than 6 days of smoking from Week 12 through the given visit.
Time frame: Week 9 through Week 52
Number of Participants With a Seven-Day Point Prevalence of Abstinence at Week 12
Responders: abstinence in previous seven days, defined in the non-treatment follow-up as: 1) "Has the participant smoked any cigarettes in the last 7 days?" = No AND 2) "Has the participant used any other tobacco products in the last 7 days?" = No. Participant a non-responder if expired CO \> 10 ppm.
Time frame: Week 12
Number of Participants With a Seven-Day Point Prevalence of Abstinence at Week 24
Responders: abstinence in previous seven days, defined in the non-treatment follow-up as: 1) "Has the participant smoked any cigarettes in the last 7 days?" = No AND 2) "Has the participant used any other tobacco products in the last 7 days?" = No. Participant a non-responder if expired CO \> 10 ppm.
Time frame: Week 24
Number of Participants With a Seven-Day Point Prevalence of Abstinence at Week 52
Responders: abstinence in previous seven days, defined in the non-treatment follow-up as: 1) "Has the participant smoked any cigarettes in the last 7 days?" = No AND 2) "Has the participant used any other tobacco products in the last 7 days?" = No. Participant a non-responder if expired CO \> 10 ppm.
Time frame: Week 52
Number of Participants With a 4 Week Point Prevalence of Smoking Cessation
Responders: participants with abstinence during the last 4 weeks of non-treatment based on answering 'no' to both of the two 'last 4 week' questions in the Nicotine Use Inventory (NUI). NUI collected information of cigarette or other nicotine use during the study.
Time frame: Week 48 through Week 52 (final 4 weeks of non-treatment period [pd])
Number of Responders With Continuous Abstinence (CA) Through Week 24
Responders: participants who remained abstinent based on 'since the last contact' question in Nicotine Use Inventory 1) "Has participant smoked any cigarettes (even a puff) since the last contact?" = No AND 2) "Has participant used any other tobacco products... since the last contact?" = No. Non- responder if the expired CO \> 10 ppm at any given timepoint.
Time frame: Week 9 through Week 24
Cigarettes Smoked Per Day
Cigarettes smoked each day during the first 3 weeks of the treatment phase.
Time frame: Day 21
Number of Long-Term Quit Responders From Week 9 Through Week 24
Responders: participants were considered Long Term Quit Responders if 1) they were responders for the primary endpoint (the 4-week CQR for Weeks 9-12) and 2) had no more than 6 days of smoking from Week 12 through the given visit.
Time frame: Week 9 through Week 24
The study was conducted in outpatients. The target population was cigarette smokers with cardiovascular disease drawn from the communities surrounding the participating clinics.
| Milestone | Varenicline (Var) | Placebo (Pbo) |
|---|---|---|
| Started | 353 | 350 |
| Completed | 302 | 289 |
| Not completed | 51 | 61 |
| Withdrew: Death | 2 | 5 |
| Withdrew: Adverse event | 8 | 5 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Lost to follow-up | 14 | 10 |
| Withdrew: Withdrawal by participant | 22 | 34 |
| Withdrew: Participant stopped study medication | 2 | 2 |
| Withdrew: Participant only allowed phone follow-up | 0 | 1 |
| Withdrew: Participant used antipsychosis meds | 0 | 1 |
| Withdrew: Lack of motivation | 1 | 0 |
| Withdrew: In prison | 0 | 1 |
| Withdrew: Protocol violation | 2 | 0 |
Participants considered Responders (4-week CQR \<=10 parts per million \<ppm\>) through reports of cigarette or other nicotine use since last study visit, confirmed by measurement of end-expiratory exhaled carbon monoxide (CO). If any CO measurement at a particular timepoint was \>10 ppm, subject was considered to be Non-Responder at that timepoint.
| participants | Varenicline (Var) | Placebo (Pbo) |
|---|---|---|
| responders | 167 | 50 |
| non-responders | 186 | 300 |
Responders: participants who remained abstinent based on 'since the last contact' question in Nicotine Use Inventory 1) "Has participant smoked any cigarettes (even a puff) since last contact?" = No AND 2) "Has participant used any other tobacco products... since last contact?" = No. Participant a non-responder if expired CO \> 10 ppm.
| participants | Varenicline (Var) | Placebo (Pbo) |
|---|---|---|
| responders | 70 | 26 |
| non-responders | 283 | 324 |
Responders: participants were considered Long Term Quit responders if 1) they were responders for the primary endpoint (the 4-week CQR for Weeks 9-12) and 2) had no more than 6 days of smoking from Week 12 through the given visit.
| participants | Varenicline (Var) | Placebo (Pbo) |
|---|---|---|
| responders | 80 | 34 |
| non-responders | 273 | 316 |
Responders: abstinence in previous seven days, defined in the non-treatment follow-up as: 1) "Has the participant smoked any cigarettes in the last 7 days?" = No AND 2) "Has the participant used any other tobacco products in the last 7 days?" = No. Participant a non-responder if expired CO \> 10 ppm.
| participants | Varenicline (Var) | Placebo (Pbo) |
|---|---|---|
| responders | 192 | 65 |
| non-responders | 161 | 285 |
Responders: abstinence in previous seven days, defined in the non-treatment follow-up as: 1) "Has the participant smoked any cigarettes in the last 7 days?" = No AND 2) "Has the participant used any other tobacco products in the last 7 days?" = No. Participant a non-responder if expired CO \> 10 ppm.
| participants | Varenicline (Var) | Placebo (Pbo) |
|---|---|---|
| responders | 124 | 57 |
| non-responders | 229 | 293 |
Responders: abstinence in previous seven days, defined in the non-treatment follow-up as: 1) "Has the participant smoked any cigarettes in the last 7 days?" = No AND 2) "Has the participant used any other tobacco products in the last 7 days?" = No. Participant a non-responder if expired CO \> 10 ppm.
| participants | Varenicline (Var) | Placebo (Pbo) |
|---|---|---|
| responders | 102 | 62 |
| non-responders | 251 | 288 |
Responders: participants with abstinence during the last 4 weeks of non-treatment based on answering 'no' to both of the two 'last 4 week' questions in the Nicotine Use Inventory (NUI). NUI collected information of cigarette or other nicotine use during the study.
| participants | Varenicline (Var) | Placebo (Pbo) |
|---|---|---|
| Number of Participants With a 4 Week Point Prevalence of Smoking Cessation | 99 | 57 |
Responders: participants who remained abstinent based on 'since the last contact' question in Nicotine Use Inventory 1) "Has participant smoked any cigarettes (even a puff) since the last contact?" = No AND 2) "Has participant used any other tobacco products... since the last contact?" = No. Non- responder if the expired CO \> 10 ppm at any given timepoint.
| participants | Varenicline (Var) | Placebo (Pbo) |
|---|---|---|
| Number of Responders With Continuous Abstinence (CA) Through Week 24 | 100 | 34 |
Cigarettes smoked each day during the first 3 weeks of the treatment phase.
| cigarettes per day | Varenicline (Var) | Placebo (Pbo) |
|---|---|---|
| Baseline | 22.2 ± 10.0 | 22.9 ± 10.9 |
| Day 1 | 17.6 ± 9.4 | 19.1 ± 10.0 |
| Day 2 | 16.8 ± 8.8 | 18.4 ± 9.6 |
| Day 3 | 15.8 ± 9.2 | 18.0 ± 10.0 |
| Day 4 | 15.7 ± 8.9 | 17.1 ± 9.6 |
| Day 5 | 15.1 ± 8.8 | 16.3 ± 8.9 |
| Day 6 | 14.4 ± 8.4 | 16.0 ± 8.9 |
| Day 7 | 13.8 ± 8.6 | 15.1 ± 8.8 |
| Day 8 | 11.7 ± 9.2 | 12.3 ± 10.5 |
| Day 9 | 9.5 ± 7.5 | 10.9 ± 9.5 |
| Day 10 | 8.9 ± 7.2 | 10.6 ± 8.6 |
| Day 11 | 8.9 ± 7.3 | 10.4 ± 8.4 |
| Day 12 | 8.7 ± 7.5 | 10.5 ± 8.3 |
| Day 13 | 8.8 ± 7.1 | 10.3 ± 8.2 |
| Day 14 | 9.3 ± 7.4 | 10.7 ± 8.6 |
| Day 15 | 8.9 ± 7.6 | 11.2 ± 9.1 |
| Day 16 | 8.8 ± 7.1 | 11.0 ± 8.7 |
| Day 17 | 8.3 ± 6.4 | 10.6 ± 8.2 |
| Day 18 | 8.2 ± 6.9 | 10.3 ± 8.8 |
| Day 19 | 7.8 ± 6.7 | 10.3 ± 8.4 |
| Day 20 | 7.9 ± 6.1 | 10.6 ± 8.3 |
| Day 21 | 7.2 ± 6.3 | 9.3 ± 8.1 |
Responders: participants were considered Long Term Quit Responders if 1) they were responders for the primary endpoint (the 4-week CQR for Weeks 9-12) and 2) had no more than 6 days of smoking from Week 12 through the given visit.
| participants | Varenicline (Var) | Placebo (Pbo) |
|---|---|---|
| responders | 117 | 42 |
| non-responders | 236 | 308 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Varenicline (Var) | — | — | — |
| Placebo (Pbo) | — | — | — |
| Event | Varenicline (Var) | Placebo (Pbo) |
|---|---|---|
| Angina pectorisCardiac disorders | 1/353 | 2/350 |
| Atrial fibrillationCardiac disorders | 1/353 | 2/350 |
| Chest painGeneral disorders | 2/353 | 2/350 |
| Acute myocardial infarctionCardiac disorders | 2/353 | 1/350 |
| Cerebrovascular accidentNervous system disorders | 2/353 | 0/350 |
| AnaemiaBlood and lymphatic system disorders | 0/353 | 1/350 |
| Acute coronary syndromeCardiac disorders | 0/353 | 1/350 |
| Cardiac failureCardiac disorders | 1/353 | 1/350 |
| Cardiac failure congestiveCardiac disorders | 0/353 | 1/350 |
| Myocardial infarctionCardiac disorders | 1/353 | 1/350 |
| Event | Varenicline (Var) | Placebo (Pbo) |
|---|---|---|
| NauseaGastrointestinal disorders | 104/353 | 30/350 |
| HeadacheNervous system disorders | 45/353 | 39/350 |
| InsomniaPsychiatric disorders | 42/353 | 23/350 |
| NasopharyngitisInfections and infestations | 23/353 | 30/350 |
| VomitingGastrointestinal disorders | 29/353 | 4/350 |
| Abnormal dreamsPsychiatric disorders | 28/353 | 6/350 |
| FatigueGeneral disorders | 25/353 | 14/350 |
| ConstipationGastrointestinal disorders | 23/353 | 7/350 |
| DiarrhoeaGastrointestinal disorders | 22/353 | 18/350 |
| DizzinessNervous system disorders | 22/353 | 16/350 |
| Age, Continuous(years) | Varenicline (Var) | Placebo (Pbo) | Total |
|---|---|---|---|
| Mean | 57.0 ± 8.6 | 56.0 ± 8.4 | 56.5 ± 8.5 |
| Sex: Female, Male(Participants) | Varenicline (Var) | Placebo (Pbo) | Total |
|---|---|---|---|
| Female | 87 | 63 | 150 |
| Male | 266 | 287 | 553 |
The record gives a start of Feb 2006, a primary completion of Nov 2007 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2009, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Varenicline